spacer
home > ebr > summer 2018 > alternative approaches
PUBLICATIONS
European Biopharmaceutical Review

Alternative Approaches

Novel cancer therapies extend far beyond traditional chemo- and radiotherapy approaches. Specific small-molecule inhibitors or antibodies targeting epitopes at the surface of cancer cells are employed to fight cancer cells. Antibody-drug conjugates deliver toxic or radioactive compounds directly to the tumour cell, and bispecific antibodies present tumour cells to the immune system. Even more advanced immune therapies such as CAR-T techniques boost the immune system by modifying T-cells. Stem cell and gene editing-based therapies are getting off the starting blocks, raising hopes towards more effective and safer cancer therapies.

Despite their structural and molecular diversity, these novel therapies have one thing in common: unlike conventional therapies, which attack every fast-dividing cell, they aim to specifically target features unique to tumour cells, allowing the use of highly potent therapies while minimising side effects on healthy tissue. Therefore, identification and characterisation of target structures is a prerequisite to the success of novel cancer therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ute Boronowsky is a freelance science and marketing writer, translator, and journalist, covering topics relevant to the biotech and pharma industry. She received a PhD in biochemistry from the University of Bochum, Germany, did post-doctoral research in biochemistry at UCLA, US, and holds a degree in science journalism from the mibeg Institute for Media in Cologne, Germany. Ute has more than 15 years working experience from sales and marketing positions in the biotech industry and is co-founder of the start-up company Cube Biotech. She is member of the Chartered Institute of Linguists, UK, and of the Science Inbound writer’s network.
spacer
Dr Ute Boronowsky
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement